Since March 2017, the Leventis Foundation has been funding the development of a Clinical Trials Unit at the Centre. This is the first time that coordinated and methodical efforts are made to promote and implement such an innovative idea.
Our objective is to conduct early clinical trials, aiming to identify the safe dose of anti-cancer substances administered to humans for the first time. To study the metabolism of the substance by the human body. Determine its effect on the human body and, finally, verify its effectiveness in controlling the disease.
Patients who have exhausted conventional treatment options for their disease are given the opportunity to access new treatments which are based on the selective targeting of molecular pathways in cancer. As a result, patients taking part in these trials will have access to drugs which are not available through the national health system, therefore increasing their treatment options.